Seeking Alpha

Dr. John Faessel's  Instablog

Dr. John Faessel
Send Message
Dr. John L. Faessel is a seasoned and respected Wall Street professional with industry-wide recognition for expertise in market strategy and analysis. He is widely recognized for his insights in public companies. For over 20-years Dr. Faessel’s ON THE MARKET reports have been widely distributed... More
View Dr. John Faessel's Instablogs on:
  • Star Scientific - Powerful New Peer Reviewed Science Shows Anatabine Inhibits Inflammation In The Central Nervous System

    Dr. John L. Faessel


    Commentary and Insights

    Powerful new peer reviewed science shows anatabine inhibits inflammation in the central nervous system

    Update: Star Scientific (STSI) Nasdaq

    Before we go on - take 85 seconds to see why there is all the interest in anatabine

    No anatabine:

    With anatabine:

    This above mentioned peer review published on 1/30/2013 (see here) follows the research that the Roskamp Institute released on 5/8/2012 (see here.)

    The study results showed that the anatabine dietary supplementation resulted in a dramatic reduction in the rate of paralysis of hind limbs of mice using a standard mouse model of multiple sclerosis [MS]. In addition to the better motor performance of the mice, there was evidence of suppression of the normal inflammatory response that accompanies neuronal destruction in this model.

    The very recent peer reviewed abstract validates the Roskamp Institutes research and therefore suggest that anatabine inhibits pro-inflammatory Th1 and Th17 cytokines which are known to play critical roles in the induction and severity of MS and Experimental Autoimmune Encephalomyelitis [EAE].

    The full title of the 26 page peer review is, "Amelioration of Experimental Autoimmune Encephalomyelitis by Anatabine," and can be viewed here.

    Noteworthy excerpts from the abstract:

    · Found that orally administered anatabine markedly suppressed neurological deficits associated with EAE.

    · Revealed that anatabine significantly reduced Th1 and Th17 cytokines known to contribute to the development of EAE.

    · Anatabine appears to significantly suppress STAT3 and p65 NFκB phosphorylation in the spleen and the brain of EAE mice.

    · Found that anatabine alleviated the infiltration of macrophages/microglia and astrogliosis and significantly prevented demyelination in the spinal cord of EAE mice

    These two transcription factors regulate a large array of inflammatory genes including cytokines suggesting a mechanism by which anatabine antagonizes pro-inflammatory cytokine production.

    The mice used in this testing were vaccinated to induce a severe inflammatory process in the brain, which has the effect of destroying neurons and causing progressive paralysis. The disease model looks very similar to that which occurs in human multiple sclerosis.

    While we know in the hierarchy of scientific investigations that animal studies do not carry the weight of human studies there is an approximate 80% correlation. Interesting for example is that 99% of mouse genes have an equivalent in humans making mice ideal for studying. Intriguing from the above link; "More so than any other genetically tractable organism, the mouse offers a close glimpse of humankind in terms of similarity in the underlying physiology, tissue structure and organization." The 2007 Nobel Prize in Physiology and Medicine was awarded to Mario Capecchi, Sir Martin Evans and Oliver Smithies for their pioneering work on gene targeting in the mouse.

    From a 2011 Mayo Clinic & Cleveland Clinic study - [that] "it is "overwhelmingly likely" that MS is fundamentally an inflammatory disease, and not a neurodegenerative Alzheimer-like disease." Published in the December 8, 2011, issue of the New England Journal of Medicine. Link here.

    Multiple sclerosis [MS] is a chronic inflammatory demyelinating autoimmune disorder of the central nervous system [CNS]. Clinical symptoms of MS not only include motor disabilities but also cognitive deficits [1] and increasing evidence indicates that axonal and neuronal injury are present both in the white and grey matter areas emphasizing a degenerative disease course [2], [3]. A variety of drugs are now approved for the treatment of MS. All of these drugs have potentially serious side effects and can suffer response failure during prolonged treatment [4], [5]. There is therefore a significant need to develop novel and safer medications to treat MS.

    And a final take away… How do we help people?

    When you read that "anatabine" reverses demyelination of the spinal cord, reduces inflammation and sees significant paralysis reduction, and it is completely safe and one can buy anatabine / Anatabloc at GNC or online? If I had MS, I certainly would want to know about it.

    MS is a cruel disease. It hits people when they are young and is difficult to diagnose early-on. Some are greatly affected, becoming severely disabled - while other can peruse relatively normal lives. For many it has fatal consequences.

    If you know anyone who has MS; copy the peer review study, copy the Star press release, show them the striking YouTube videos above - get it to them, their doctor, caregivers etc... No safety issues or side effects... Help save a life…

    Disclaimer; I bought shares of Star Scientific in the open market and have no relationship with the company.

    Feb 21 11:02 AM | Link | Comment!
  • ON THE MARKET -- The Market Looks To Be Losing Steam

    Pre-market - Monday 2-11-2013

    "The most important single central fact about a free market is that no exchange takes place unless both parties benefit."

    Milton Friedman

    Dr. John L. Faessel


    Commentary and Insights

    Quotes of the day

    "The impact on the broader economy and financial markets of the problems in the subprime market seems likely to be contained."

    ~ Ben Bernanke in 2007 ~

    Federal Reserve Chairman

    BULLISH SENTIMENT continues to run HOT * but the McClellan Oscillator is in Neutral

    The Stock Market continues to advance albeit on low and declining volume. Over the last 15-days of trading there have been 4-days of distribution and those points to institutional selling. The near straight up extended trajectory has 'price' near the top of the channel that extends off the mid-November lows. Sentiment is running hot, but off its recent highs of the last few weeks* and the McClellan Oscillator is in Neutral - so my favorite overboughtness / oversoldness indicator suggests more upside could be easily absorbed by the market. The Stochastic's - slow K (94.49) and fast (98.38) indicates an overbought market suggesting a possible retreat. Also the Bond market and Dollar technical's that were on life support just recently have eased off the critical list.

    Also of note is that there have been some unusually large positioning of 'puts' in defensive set-ups in the and Select SPDR- Financial (NYSEARCA:XLF) and Russell 2000 index (NYSEARCA:IWM) but naturally there is a latent buy built into the other side of the option that's bullish. These big 'hedges' have been used by savvy option players who have been out in front of the news re the Euro Crisis. Note the Key Euro Bond yields have been creeping up recently.

    The Santa Clause rally continues - but looks to be losing steam…


    The S&P 500 (SPX) is priced at the lowest multiple of earnings at a bull-market peak since World War II, roughly 14.5 X what companies earned over the past year, versus 28.2 X at the 2000 peak, or 16.8 X in 2007. Also; Cash makes up a whopping 14% of corporate assets today, 2X the twenty years ago. Yet capital expenditure accounts for just 16.4% of cash, well below the 28.1% average since 1990. I can read this as worry about what investors and corporate America see going on - from my perch we & Europe are being led by a bunch of economic imbeciles.


    According to the U.S. Commerce Department - China surpassed the U.S. to become the world's biggest trading nation last year. U.S. exports and imports of goods last year totaled $3.82 trillion. China's was $3.87 trillion said customs administration re 2012 amounted to

    Once again: Two key items to keep in recall;

    On December 31 and January 2 - 90% of stocks advanced on back-to-days back suggests that the very strong rising tide will continue to search. Usually, after back-to-back 90% up days the market has advanced an additional 6.8% within a month 83% of the time - and 12.8% three-months later 100% of the time.

    S&P 500 (SPX) profits are set to exceed $1 trillion in 2013, nearly 30% higher than when the index last hit a high in 2007. Even if PE multiples don't expand, the (SPX) is on pace to hit a record. See Bloomberg


    Another repeat if you missed it last week - a MUST READ - From Bill Gross's Monthly PIMCO letter:

    (1) Position for eventual inflation: the end stage of a supernova credit explosion is likely to produce more inflation than growth, and more chances of inflation as opposed to deflation. In bonds, buy inflation protection via TIPS; shorten maturities and durations; don't fight central banks - anticipate them by buying what they buy first; look as well for offshore sovereign bonds with positive real interest rates (Mexico, Italy, Brazil, for example).

    (2) Get used to slower real growth: QEs and zero-based interest rates have negative consequences. Move money to currencies and asset markets in countries with less debt and less hyperbolic credit systems. Australia, Brazil, Mexico and Canada are candidates.

    (3) Invest in global equities with stable cash flows that should provide historically lower but relatively attractive returns.

    (4) Transition from financial to real assets if possible at the margin: buy something you can sink your teeth into - gold, other commodities, anything that can't be reproduced as fast as credit. Think of PIMCO in this transition. We hope to be "Your Global Investment Authority." We have a product menu to assist.

    (5) Be cognizant of property rights and confiscatory policies in all governments.


    Last week the S&P 500 (SPX) Index of U.S. stocks surged to new highs adding another 0.31% to the prior week's continuing breakout.

    The S&P 500 (SPX) closed Friday at 1517.93. A week ago last Friday it was 1513.14.

    The October 2007 (SPX) all-time highs and price resistance is at 1576

    Short term price support is at 1515

    Hourly channel support is at 1503

    Then deep channel and trend line support of 1404.

    November retreat lows / and Price support is at 1343.

    The 50-day moving average support is at 1456

    The 200-day moving average support is at 1403


    Greek, Spanish and Italian short and long-term bond yields moved higher again last week off their January 11th lows;

    · Greek 10-year yields have slipped to 10.83% - down from a high of 24.41%

    · Italy 10-year (gross) bond yield - 4.60% off cycle highs of 7.29%.

    · Spanish 10-year (generic) bond yield - 5.39% off cycle highs of 7.41%.


    Friday's key indicators and metrics:

    Cycle highs or lows are in red

    · McClellan Oscillator is NEUTRAL at plus 9

    · US Dollar Index - 80.316

    · Japanese Yen - 1.0777

    · Euro - 1.3366

    · Swiss Franc - 1.0907

    · 3-month $ LIBOR - 0.311

    · VIX - 13.02

    · Aussie Dollar - 1.0286

    · Lumber (NASDAQ:CME) - 387.8

    · CBOE Put / Call Volume Ratio - 0.90

    · Natural Gas (Globex) - 3.272

    · Canadian Dollar - 0.9964

    · Silver (COMEX) - 31.441

    · Gold (COMEX) - $1666.9

    · Copper - 3.7595

    · Crude oil (NYMEX) - $95.72

    · Brent Crude - $113.18

    · The Treasury 10-year yield - 1.95%

    · The 30-year Treasury - 3.17%


    * This week's Investor Sentiment.

    The Bullishness / Bearishness complex is continuing to post highly Bullish reads suggesting DANGER and a significant possibility of a market retreat. During the EURO Crisis & fiscal cliff rumbles overall sentiment was indicating high distress; a bullish signal.

    (High BULLISH readings in the Investor Sentiment Readings usually are signs of Market tops; low ones, market bottoms.)

    · The American Association of Individual Investors [AAII] Investor Sentiment Survey of BULLISHNESS fell to 42.8% from 48%. The survey posted recent highs of 52.3% three weeks ago. It posted cycle lows of 22.2% on 7/23/2012 the lowest percentile since August 2010.

    · The Market Vane (Market Letter Survey) once again registered a multi-year high of 69% well past the highest bullish % levels of January 2010 and April 2010 - both intermediate market tops. In October 2007 it topped at 70% bullish.

    · Consensus Index BULLISH rose to new recent highs of 71% up from 70% the prior period. It posted Cycle highs @ 73% about four-months ago.

    The exclusive CONSENSUS BULLISH SENTIMENT INDEX is the premium gauge of positions and attitudes of major professional brokerage firms and advisors as interpreted and recorded by CONSENSUS, INC.

    · The AAII Investor Survey of BEARISHNESS rose to 29.6% from 24.3 the prior period. Six-weeks ago it was 36.2%. On August 4th 2011 it posted cycle highs of 49.9% in Bearishness.

    The Citigroup "Panic / Euphoria" Model stayed at a plus 38%. At the end of June 2011 it ticked cycle lows of minus 0.31 in the Panic mode. The model is still registering in the high end of the Neutral zone.

    The BARRON's Confidence Index is 68.2 -. One-year ago it was 67.3.

    The Confidence Index is the premier measure of how the bond markets trillions (total global is around $91 trillion and USA is 39% of that) are allocated: (The bond market is twice the size of the stock market.) The Index is the High-grade bond index divided by intermediate-grade index. A decline in latter vs. former - generally indicates rising confidence, pointing to higher stocks.

    Feb 11 11:22 AM | Link | Comment!
  • Update: Star Scientific - Let's Restate The Facts And Science:

    Dr. John L. Faessel


    Commentary and Insights

    Update: Star Scientific (STSI) Nasdaq

    Let's restate the facts and science:

    1. Anatabine / Anatabloc is a potent, safe, non-addictive alpha-7 nicotinic receptor agonist that acts both on the CNS and immune system to suppress neurological and systemic inflammation.

    2. Anatabine / Anatabloc has been demonstrated to suppress many important biochemical markers associated with Alzheimer's and autoimmune disease in-vitro (i.e. in test tubes at the lab bench)

    3. Anatabine / Anatabloc has been demonstrated to ameliorate autoimmune thyroiditis (Hashimoto's disease) and biomarkers of Alzheimer's disease in cutting-edge animal models (i.e. in mice at the vivarium)

    4. Anatabine / Anatabloc has been demonstrated to suppress important biomarkers of inflammation and Hashimoto's disease in humans using rigorous, FDA approved, randomized, double-blinded, placebo-controlled studies (i.e. in the clinic). Anatabine / Anatabloc is clinically proven to significantly lower levels of anti-thyroid antibodies, improve thyroid volume and vascularization, and lower C-reactive protein (CRP) levels.

    5. Anatabine / Anatabloc is being evaluated by Star in at least two ongoing FDA approved clinical trials as treatments for Alzheimer's disease and rosacea.

    6. The clinical programs are run in collaboration with external key opinion leaders in the fields, including eminent endocrinologist and thyroid expert Dr. Paul Ladenson, and Dr. Michael Mullan of the Roskamp Institute, who is a recognized authority in Alzheimer's disease.

    Star Scientific has successfully advanced Anatabine / Anatabloc through a rigorous progression from lab bench through animal models and into the clinic with success at every stage, clear signals of efficacy in major disease areas, and no - absolutely no adverse events related to toxicity. All the scientific and clinical data indicates that the compound is safe, effective, and well tolerated.

    Four (4) peer-review papers have been published:

    1. "Anatabine lowers Alzheimer's Aβ production in vitro and in vivo" published in the European Journal of Pharmacology - 11/30/11

    2) "Anatabine Ameliorates Experimental Autoimmune Thyroiditis" published in Endocrinology - Online 7/17/12, Print 9/1/12

    3) "Anti-inflammatory activity of anatabine via inhibition of STAT3 phosphorylation" published in the European Journal of Pharmacology - 1/5/13

    4) "Amelioration of Experimental Autoimmune Encephalomyelitis by Anatabine" published in PLOS ONE - 1/30/13

    Anatabine / Anatabloc is on the front burner of science

    The interest in alpha-7 nicotinic receptor agonists such as anatabine continues to grow, as reflected by an increasing number of clinical trials; a sampling of them can be seen on the U.S National Institutes of Health website here. Pharma is scrambling to find and secure intellectual property rights on alpha-7 nicotinic receptor agonists that are safe, effective, and well tolerated. Anatabine / Anatabloc is a safe, effective, and well-tolerated alpha-7 nicotinic acid receptor agonist that acts both on the CNS and immune system to suppress neurological and systemic inflammation.

    Anatabine has also been demonstrated to affect the JAK-STAT pathway by suppressing STAT3 phosphorylation, inhibits TNF-alpha and NF-kB levels in-vitro.

    And above all, anatabine / Anatabloc has recently demonstrated proof of concept and shown efficacy in the clinic in humans.

    In sum; by all indications, anatabine / Anatabloc appears to be the current gold standard in the field and adds a substantial multiplier in gauging its and the Star's potential and value.

    As of today Institutional Ownership is at a new high [2/8/2013]

    (Less than 5% holders)

    Total Number of Holders


    % of Shares Outstanding


    Total Shares Held


    Link Nasdaq detail here


    Disclosure: I am long STSI.

    Tags: RCPI
    Feb 08 2:47 PM | Link | 4 Comments
Full index of posts »
Latest Followers
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.